Fundraising for a total of €3.1 million, through the issue of 2,412,511 new shares Cash position of around €7,8 million to pursue clinical development of Batten-1 The American Beyond Batten Disease Foundation acquires a 11.6% equity stake in the Company (on a non-diluted post-fundraising basis) Strong demand by individual investors, for final participation of €0.6 million, through the PrimaryBid platform Lyon, France - July 12, 2023 - 7:30 am CEST - Theranexus, an innovative...